≥99% HPLCIntranasal spray

AC-Selank + AC-Semax (Nasal Spray)

Name: AC-Selank + AC-Semax (Nasal Spray)
Brand: Dripfy
Availability: InStock

What it is?

This is an intranasal blend of two Russia-region peptides: Selank, an anxiolytic heptapeptide derived from tuftsin, and Semax, a synthetic analog of an ACTH(4-10) fragment studied for nootropic and neuroprotective signalling. These peptides are regulated for certain uses in Russia but remain investigational and unapproved in the EU/UK.

Dripfy Advantage

Nootropic signalling: Semax is studied for effects on attention and mental fatigue via neuromodulatory pathways.
Neurotrophic support: Semax is associated in research with brain-derived neurotrophic factor (BDNF) and dopaminergic/serotonergic signalling.
Anxiolytic pathway: Selank is investigated for stress- and anxiety-related modulation.
Intranasal route: Delivered as a spray to explore nose-to-brain access pathways.
Combined framing: The blend overlays focus- and calm-related signalling, though the interaction is not well characterised in humans.

Research & Investigational Focus

Cognitive/attention research: Investigated for attention and mental-fatigue support (Semax component).
Anxiety modulation: Studied for stress-response and anxiety-related signalling (Selank component).
Neuroprotective signalling: Explored in early research for neurotrophic (BDNF) pathways.
Combined focus/calm frameworks: Positioned for physician-directed research combining both pathways.

Composition & Formulation

Format: Intranasal spray
Purity: ≥99% by HPLC/MS
Supervision: Physician-directed use only

€622

Order by email

Submit an enquiry and we arrange the consultation, physician review and shipping. Physician recommendation required; not medical advice.

Purity: ≥99%
Form: Intranasal spray
Download Certificate of Analysis: Certificate of Analysis available on request

Important medical notice

A physician recommendation is mandatory before use.
The information on this website is educational only and is not medical advice, diagnosis, or treatment.
Always consult a qualified physician before starting any peptide.
Dosing is individualised and determined by your treating physician.

Peptide Practice Guide

Each card summarises what the peptide is studied for and its evidence strength. It is not a recommendation. Dosing and suitability are decided by your physician.

AC-Selank + AC-Semax (Nasal Spray)

Investigational nootropic/anxiolytic peptide blend, intranasal (Selank + Semax) · Intranasal spray

D· Preliminary evidence

This intranasal blend combines two Russia-region peptides. Selank is a tuftsin-derived heptapeptide studied for anxiolytic effects and neuro-immune modulation. Semax is a synthetic analog of the ACTH(4-10) fragment investigated for nootropic and neuroprotective signalling, including associations with brain-derived neurotrophic factor (BDNF) and dopaminergic and serotonergic pathways. Intranasal delivery is used to explore nose-to-brain access; in Russia these peptides are regulated for certain uses, while elsewhere they remain investigational and unapproved, and the combined effect is not characterised in controlled human studies.

Studied use areas

Investigated for attention and mental-fatigue support (Semax component)
Studied for stress-response and anxiety-related signalling (Selank component)
Explored in early research for neuroprotective and neurotrophic (BDNF) pathways
Positioned for physician-directed research combining focus and calm pathways

Safety & status

Outside Russia these peptides are investigational and not EU/UK-approved; combined human safety and efficacy data are limited
Blending two actives compounds the uncertainty, and intranasal delivery can cause local nasal irritation — physician supervision is mandatory
Not for use in pregnancy or breastfeeding, and not a treatment for any neurological or psychiatric condition

⚕ Clinical note: This is educational information, not medical advice. This Selank + Semax intranasal blend is investigational and unapproved in the EU/UK, and combining compounds increases the uncertainty; it is intended for physician-directed use only and is not a treatment for any cognitive, neurological, or psychiatric condition.

Evidence: Grade D — investigational; limited human data, mainly preclinical · References: Dolotov OV et al., Journal of Neurochemistry, 2006; Zozulya AA et al., Bulletin of Experimental Biology and Medicine, 2008; Medvedeva EV et al., Journal of Molecular Neuroscience, 2014